9.03
Precedente Chiudi:
$9.09
Aprire:
$9.09
Volume 24 ore:
45,521
Relative Volume:
0.39
Capitalizzazione di mercato:
$129.91M
Reddito:
$166.88M
Utile/perdita netta:
$-74.18M
Rapporto P/E:
-1.7811
EPS:
-5.07
Flusso di cassa netto:
$1.14M
1 W Prestazione:
-4.39%
1M Prestazione:
+4.12%
6M Prestazione:
-33.14%
1 anno Prestazione:
-64.28%
Anika Therapeutics Inc Stock (ANIK) Company Profile
Nome
Anika Therapeutics Inc
Settore
Telefono
(781) 457-9000
Indirizzo
32 WIGGINS AVENUE, BEDFORD, MA
Confronta ANIK con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ANIK
Anika Therapeutics Inc
|
9.01 | 131.93M | 166.88M | -74.18M | 1.14M | -5.07 |
![]()
ZTS
Zoetis Inc
|
144.09 | 63.58B | 9.39B | 2.62B | 2.22B | 5.8121 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
13.91 | 43.58B | 29.96B | 957.25M | 4.77B | 0.2956 |
![]()
HLN
Haleon Plc Adr
|
9.205 | 40.83B | 14.26B | 1.98B | 2.47B | 0.4327 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.80 | 23.07B | 16.70B | -157.13M | 1.19B | -0.1446 |
![]()
UTHR
United Therapeutics Corp
|
430.14 | 19.61B | 3.08B | 1.24B | 1.07B | 25.61 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-17 | Iniziato | B. Riley Securities | Buy |
2024-11-01 | Reiterato | Barrington Research | Outperform |
2023-08-14 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
2023-03-07 | Downgrade | Barrington Research | Outperform → Mkt Perform |
2022-11-09 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
2022-10-14 | Ripresa | Stephens | Equal-Weight |
2022-03-09 | Downgrade | Barrington Research | Outperform → Mkt Perform |
2022-03-09 | Downgrade | Stephens | Overweight → Equal-Weight |
2021-11-16 | Iniziato | Stephens | Overweight |
2021-07-16 | Iniziato | UBS | Neutral |
2020-12-16 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
2020-05-08 | Downgrade | Barrington Research | Outperform → Mkt Perform |
2020-01-21 | Aggiornamento | Sidoti | Neutral → Buy |
2020-01-10 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
2019-11-05 | Iniziato | BWS Financial | Sell |
2019-09-24 | Reiterato | Barrington Research | Outperform |
2019-09-23 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
2019-07-25 | Aggiornamento | First Analysis Sec | Neutral → Strong Buy |
2019-02-22 | Downgrade | First Analysis Sec | Outperform → Neutral |
2019-02-22 | Downgrade | Sidoti | Buy → Neutral |
2018-07-27 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
2018-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
2018-06-20 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
2018-05-04 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
2018-02-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
2018-01-24 | Aggiornamento | First Analysis Sec | Equal-Weight → Overweight |
2017-10-27 | Reiterato | Barrington Research | Outperform |
2016-05-09 | Aggiornamento | Singular Research | BUY - Long-Term → Buy |
2016-04-27 | Downgrade | Northland Capital | Outperform → Market Perform |
2016-02-26 | Reiterato | Barrington Research | Outperform |
Mostra tutto
Anika Therapeutics Inc Borsa (ANIK) Ultime notizie
Multi factor analysis applied to Anika Therapeutics Inc.Weekly Investment Report & Community Verified Swing Trade Signals - newser.com
Does Anika Therapeutics Inc. qualify in momentum factor screeningWeekly Volume Report & Weekly High Conviction Ideas - newser.com
Why Anika Therapeutics Inc. stock could outperform in 2025Quarterly Trade Summary & Free Verified High Yield Trade Plans - newser.com
Is Anika Therapeutics Inc. stock positioned for long term growthQuarterly Portfolio Review & Verified Technical Signals - newser.com
How to escape a deep drawdown in Anika Therapeutics Inc.2025 Valuation Update & Safe Capital Growth Tips - newser.com
Best data tools to analyze Anika Therapeutics Inc. stockJuly 2025 Rallies & Fast Exit and Entry Strategy Plans - newser.com
What institutional flow reveals about Anika Therapeutics Inc.2025 Valuation Update & Long Hold Capital Preservation Tips - newser.com
Is Anika Therapeutics Inc. (AKP) stock attractive for growth fundsPortfolio Value Summary & Weekly Momentum Stock Picks - newser.com
Anika Therapeutics Shares Face Mounting Pressure Amid Technical and Legal Woes - AD HOC NEWS
How to recover losses in Anika Therapeutics Inc. stockJuly 2025 EndofMonth & Risk Adjusted Buy and Sell Alerts - newser.com
Anika Therapeutics Inc. stock trend outlook and recovery path2025 Short Interest & Community Consensus Picks - newser.com
ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. - GlobeNewswire
United States Adhesion Barrier Market Set for Explosive Growth: - openPR.com
Can Anika Therapeutics Inc. (AKP) stock sustain double digit ROEJuly 2025 Closing Moves & Scalable Portfolio Growth Ideas - newser.com
Weiss Ratings Reiterates "Sell (E+)" Rating for Anika Therapeutics (NASDAQ:ANIK) - MarketBeat
Orthopedic Digit Implants Market Report 2025-2033, with Profiles of Extremity Medical, Stryker, Zimmer, Smith & Nephew, Depuy, Arthrex, Acumed, Anika Therapeutics, VILEX, and Paragon 28 - Ortho Spine News
Orthopedic Digit Implants Market Report 2025-2033, with - GlobeNewswire
What technical models suggest about Anika Therapeutics Inc.’s comebackM&A Rumor & Stock Portfolio Risk Control - newser.com
Published on: 2025-10-05 06:33:40 - newser.com
Predicting Anika Therapeutics Inc. trend using moving averagesJuly 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com
Anika Therapeutics Inc. stock trendline breakdownEarnings Recap Report & Fast Gaining Stock Reports - newser.com
Trend analysis for Anika Therapeutics Inc. this weekFed Meeting & Risk Managed Investment Entry Signals - newser.com
Leading vs lagging indicators on Anika Therapeutics Inc. performanceM&A Rumor & Real-Time Sentiment Analysis - newser.com
Analyzing Anika Therapeutics Inc. with multi timeframe chartsMarket Sentiment Report & Community Verified Trade Alerts - newser.com
Using data filters to optimize entry into Anika Therapeutics Inc.New Guidance & High Conviction Investment Ideas - newser.com
Published on: 2025-10-03 01:07:01 - newser.com
How to monitor Anika Therapeutics Inc. with trend dashboardsEarnings Trend Report & High Conviction Investment Ideas - newser.com
What analysts say about Anika Therapeutics Inc stockMean Reversion Trades & Big Gains Small Investment - earlytimes.in
Can T I Global Limited Survive Disruption in Its Core IndustryRSI Overbought/Oversold & Double Digit Trading Ideas - earlytimes.in
Anika Therapeutics Inc Azioni (ANIK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Anika Therapeutics Inc Azioni (ANIK) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Nunes Anne | SVP, Chief Operations Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
3,637 |
0 |
21,722 |
Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):